Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 36 Month Multi-center, Open Label, Randomized, Comparator Study to Evaluate the Efficacy and Safety of Everolimus Immunosuppression Treatment in Liver Transplantation for Hepatocellular Carcinoma Exceeding Milan Criteria

NCT02081755 is registered in ClinicalTrials.gov with Baylor Research Institute as lead sponsor.

NCT NCT02081755
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02081755 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 36 Month Multi-center, Open Label, Randomized, Comparator Study to Evaluate the Efficacy and Safety of Everolimus Immunosuppression Treatment in Liver Transplantation for Hepatocellular Carcinoma Exceeding Milan Criteria
Lead sponsor
Baylor Research Institute
Phase
Phase 4
Overall status
Enrolling by invitation
Start date
March 31, 2014
Completion date
March 31, 2027
Enrollment
336 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, hepatocellular